Najit Technologies

What Najit Technologies does

Najit Technologies, Inc. (NTI) is a privately held, clinical-stage vaccine development company headquartered in Beaverton, Oregon, founded in 2007. The company is dedicated to developing safe and effective vaccines against infectious diseases of global importance, with particular emphasis on vulnerable populations (infants, elderly, and immunocompromised individuals) who cannot safely receive live virus vaccines. NTI's pipeline includes West Nile Virus (Phase 1), Chikungunya (Phase 1), Yellow Fever (preclinical, NIH-funded), Campylobacter (preclinical, with 83% efficacy demonstrated in non-human primates), and Universal Flu (research stage).

The company's core technology is the proprietary HydroVax platform, an oxidation-based vaccine inactivation process that preserves neutralizing and T-cell epitopes while replacing live vaccines with safer inactivated counterparts. The platform supports heat-stable, preservative-free formulations amenable to difficult cold-chain environments and can be rapidly adapted to new targets. NTI holds 15 issued patents across the U.S., Europe, Canada, Japan, Australia, and India covering dual oxidation processes and polyatomic oxyanion protection of antigens, and has built cGMP-compliant manufacturing capability including a proprietary Vero cell line.

NTI's business model is grant- and partnership-driven. Primary funding comes from the National Institutes of Health (notably a $3M grant in 2019) and Oregon state programs. Core research collaborations include Oregon Health & Science University (where President and CSO Dr. Mark K. Slifka holds a joint faculty position), Washington University-St. Louis, and the Oregon National Primate Research Center. NTI is actively seeking industry and academic partners for co-development, marketing, distribution, and sub-licensing, with future revenue expected to flow from licensing royalties, milestone payments, and government procurement rather than direct sales. The company is founder-controlled, has 1-10 employees, and has not disclosed any private equity or venture capital financing.

Name

Najit Technologies

Legal name

Najit Technologies, Inc.

Website

https://najittech.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Najit Technologies is a privately held, clinical-stage vaccine developer using its proprietary HydroVax oxidation-based inactivation platform to create safer inactivated vaccines for infectious diseases of global importance, targeting vulnerable populations, endemic regions, and military and traveler markets.

Ownership category

akta.pro rank

Product category

Vaccine Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Travel & Tropical Disease Vaccines (HLAIAEAE), Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA)

Keywords

• Inactivated vaccine development
• Infectious disease vaccines
• Vaccine platform technology
• Clinical-stage biotechnology
• Vaccine licensing partnerships

Headquarters

HQ city

Beaverton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Vaccine Development and Licensing: Revenue generation through development and licensing of proprietary vaccines. The company is developing vaccines against infectious diseases of global importance and seeks partnerships for co-development, marketing, distribution, and sub-licensing agreements.
2. Government and NIH Grants: Funding received from the National Institutes of Health (NIH) for vaccine development programs, including West Nile Virus vaccine development and Yellow Fever vaccine development in partnership with OHSU.
3. Strategic Partnerships and Collaborations: Collaborations with academic and industry partners for co-development of products, potentially including milestone payments and downstream royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Najit Technologies develops safe and effective inactivated vaccines against infectious diseases of global importance using its proprietary HydroVax™ oxidation-based vaccine platform. The company's pipeline includes West Nile Virus, Yellow Fever, Chikungunya, Campylobacter, and Universal Influenza vaccine candidates targeting vulnerable populations such as infants, elderly, and immunocompromised individuals for whom live vaccines are contraindicated. The company pursues NIH grant funding and licensing/co-development partnerships rather than direct commercialization.

Product overview

Najit Technologies is a vaccine development company with a portfolio of infectious disease vaccines built on its proprietary HydroVax™ platform. The platform serves as the core technology foundation for all vaccine candidates, enabling creation of safer, inactivated formulations that preserve important immunological epitopes. The product pipeline includes: West Nile Virus Vaccine (Phase 1 clinical trial), Yellow Fever Virus Vaccine (preclinical/NIH-funded), Chikungunya Virus Vaccine (Phase 1 clinical testing), Campylobacter Vaccine (preclinical), and Universal Flu Vaccine (research stage). All vaccines leverage the HydroVax platform's oxidation-based inactivation technology, which provides advantages for heat-stable, preservative-free formulations suitable for vulnerable populations including infants, elderly, and immunocompromised individuals.

Differentiator

Problem solved

Functional benefit

Brands

• HydroVax: Proprietary vaccine platform technology used for developing safer, more effective inactivated vaccines against infectious diseases.

Products and services

• HydroVax Vaccine Platform Proprietary oxidation-based vaccine platform that enables creation of safer, inactivated vaccines by preserving immunological epitopes while replacing live virus vaccines. Supports heat-stable, preservative-free formulations and enables rapid incorporation of new vaccine targets or combination of viral antigens for broad virus family protection.
• West Nile Virus Vaccine (HydroVax-001) Inactivated whole-virus West Nile Virus vaccine using the HydroVax platform. Developed in partnership with Oregon Health & Science University and Washington University-St. Louis, with NIH funding. Designed to address West Nile Virus where no licensed human vaccine currently exists and where mortality reaches 7-14% overall and up to 35% in elderly patients.
• Yellow Fever Virus Vaccine Inactivated Yellow Fever vaccine developed with the HydroVax platform and funded by NIH in partnership with OHSU. Designed as a safer alternative to current live yellow fever vaccine, which causes 47 severe adverse events per million vaccinations, vaccine-associated neurological disease at 1:10,000, and viscerotropic disease in adults over 60 at 1:50,000 with 50% mortality. Intended for immunologically vulnerable individuals including infants and elderly.
• Chikungunya Virus Vaccine Highly potent inactivated Chikungunya vaccine candidate using the HydroVax platform. Demonstrated full protection against disease in animal models. No licensed human Chikungunya vaccine currently exists, addressing a significant unmet need for military personnel and travelers in endemic regions.
• Campylobacter Vaccine Novel inactivated Campylobacter vaccine demonstrating 83% vaccine efficacy in outdoor-housed non-human primates in a natural exposure model. Addresses bacterial gastroenteritis causing 400-500 million cases per year globally with up to $5.6 billion in annual costs in the U.S. alone. Targets a disease with substantial developing-world burden.
• Universal Flu Vaccine Next-generation HydroVax vaccine candidate using site-directed oxidation-based inactivation technology to produce heat-stable vaccine formulations structurally similar to native live virus, designed to induce broad protective immunity across influenza strains.

Quantifiable outcome

• 83% vaccine efficacy against Campylobacter in outdoor-housed non-human primates in natural exposure model
• +4 more outcomes

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and major.

• Oregon Health & Science University (OHSU)coreStrategic or Co-development PartnerNTI partnered with OHSU for development of West Nile Virus vaccine and Yellow Fever vaccine using the proprietary HydroVax platform. Dr. Slifka holds joint faculty position at OHSU and the collaboration has included advanced research activities. Multiple publications co-authored with OHSU researchers in Nature Communications, Cell Reports Medicine, and other journals.
• Washington University-St. LouismajorStrategic or Co-development PartnerNTI partnered with Washington University-St. Louis along with OHSU to develop an inactivated whole-virus West Nile Virus vaccine using its proprietary HydroVax platform. Pre-clinical studies demonstrated significant immunity and protection.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Valneva: Valneva is a specialty vaccine company that developed and commercialized IXCHIQ, the first FDA-approved Chikungunya vaccine. It is directly comparable to NTI because both target Chikungunya and other travel/tropical infectious diseases, and both run clinical-stage vaccine pipelines competing in overlapping indications.
• Emergent BioSolutions: Emergent BioSolutions is a clinical-stage and commercial vaccine developer focused on infectious diseases including travel/zoonotic vaccines. Comparable to NTI because both develop inactivated/specialty vaccines targeting high-burden infectious diseases with public health and government procurement channels.
• Novavax: Novavax is a vaccine platform company that built a recombinant nanoparticle technology to rapidly address multiple infectious disease targets. Comparable to NTI because both use proprietary vaccine platforms to address multiple infectious disease targets in clinical-stage development with platform-leverage theses.
• Bavarian Nordic: Bavarian Nordic is a clinical/commercial vaccine developer with a pipeline spanning travel, infectious disease, and specialty indications. Comparable to NTI because both operate platform-based vaccine development targeting niche infectious diseases and government/public health customers.

Emerging players

• GeoVax Labs: GeoVax is a clinical-stage vaccine platform company developing candidates against infectious diseases and emerging pathogens. Comparable to NTI because both are early-stage platform vaccine developers focused on infectious diseases with unmet needs and government/public-sector demand.
• Vaxart: Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines against infectious diseases. Comparable to NTI because both are small-cap clinical-stage vaccine platform developers pursuing differentiated routes of administration/immunology for infectious diseases.
• Codagenix: Codagenix is a clinical-stage vaccine developer using codon deoptimization to create live-attenuated vaccines for infectious diseases. Comparable to NTI because both are early-stage platform-based vaccine developers applying proprietary technology to infectious disease targets.

Broad incumbents

• Sanofi Pasteur: Sanofi Pasteur is the world's largest vaccine manufacturer with established travel/tropical franchises including YF-VAX (live-attenuated yellow fever vaccine). Comparable to NTI as a broad incumbent that dominates the same travel/tropical disease vaccine market where NTI's inactivated alternatives would compete.
• Takeda (Vaccines Business Unit): Takeda's vaccine business includes inactivated travel/dengue vaccines and is a global vaccine distributor. Comparable to NTI as a broad incumbent that competes in travel/tropical disease vaccines with established global distribution networks.

Others

• Moderna: Moderna is a clinical/commercial vaccine platform company with an mRNA technology platform addressing multiple infectious disease targets. Comparable to NTI thematically as a platform-based infectious disease vaccine developer, though using a different (mRNA) technology modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/najit-technologies-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Najit Technologies